147 related articles for article (PubMed ID: 33706076)
1. Novel PROTACs for degradation of SHP2 protein.
Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine phosphatase Shp2 positively regulates cold stress-induced tyrosine phosphorylation of SIRPĪ± in neurons.
Jingu D; Iino M; Kawasaki J; Urano E; Kusakari S; Hayashi Y; Matozaki T; Ohnishi H
Biochem Biophys Res Commun; 2021 Sep; 569():72-78. PubMed ID: 34237430
[TBL] [Abstract][Full Text] [Related]
3. SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function.
Strazza M; Adam K; Lerrer S; Straube J; Sandigursky S; Ueberheide B; Mor A
Inflammation; 2021 Aug; 44(4):1529-1539. PubMed ID: 33624224
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity.
Miao J; Bai Y; Miao Y; Qu Z; Dong J; Zhang RY; Aggarwal D; Jassim BA; Nguyen Q; Zhang ZY
Molecules; 2023 Oct; 28(19):. PubMed ID: 37836790
[TBL] [Abstract][Full Text] [Related]
5. Allosteric modulation of SHP2: Quest from known to unknown.
Wang N; Zhu S; Lv D; Wang Y; Khawar MB; Sun H
Drug Dev Res; 2023 Nov; 84(7):1395-1410. PubMed ID: 37583266
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
[TBL] [Abstract][Full Text] [Related]
7. NanoSHP099-Targeted SHP2 Inhibition Boosts Ly6C
Ying K; Xin W; Xu Y; Lv D; Zhu H; Li Y; Xu W; Yan C; Li Y; Cheng H; Chen E; Ma G; Zhang X; Ke Y
Adv Sci (Weinh); 2024 Apr; 11(13):e2308166. PubMed ID: 38247197
[TBL] [Abstract][Full Text] [Related]
8. Allosteric inhibitor of SHP2 enhances macrophage endocytosis and bacteria elimination by increasing caveolae activation and protects against bacterial sepsis.
Li T; Xu B; Li W; Cheng X; Tantai W; Zheng H; Zhao L; Li N; Han C
Pharmacol Res; 2024 Mar; 201():107096. PubMed ID: 38320736
[TBL] [Abstract][Full Text] [Related]
9. Discovery of ellagic acid as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 (SHP2) for cancer treatment: In vitro and in silico study.
Ma CH; Zhao JF; Zhang XG; Ding CH; Hao HH; Ji YH; Li LP; Guo ZT; Liu WS
Int J Biol Macromol; 2024 Jan; 254(Pt 2):127845. PubMed ID: 37935292
[TBL] [Abstract][Full Text] [Related]
10. Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy.
Wang S; Battigelli A; Alkekhia D; Fairman A; Antoci V; Yang W; Moore D; Shukla A
RSC Adv; 2020 May; 10(34):20073-20082. PubMed ID: 35520441
[TBL] [Abstract][Full Text] [Related]
11. Direct-to-biology platform: From synthesis to biological evaluation of SHP2 allosteric inhibitors.
Ponzi S; Ferrigno F; Bisbocci M; Alli C; Ontoria JM; Petrocchi A; Toniatti C; Torrente E
Bioorg Med Chem Lett; 2024 Mar; 100():129626. PubMed ID: 38266789
[TBL] [Abstract][Full Text] [Related]
12. A Novel Gain-of-Signal Assay to Detect Targeted Protein Degradation.
Hoffman M; Cheah KMH; Wittrup KD
ACS Synth Biol; 2024 Jan; 13(1):220-229. PubMed ID: 38171010
[TBL] [Abstract][Full Text] [Related]
13. Novel Pyrazolopyrazine Compounds as SHP2 Inhibitors for Treating Glioblastoma.
Sabnis RW
ACS Med Chem Lett; 2023 Oct; 14(10):1336-1337. PubMed ID: 37849559
[TBL] [Abstract][Full Text] [Related]
14. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
[TBL] [Abstract][Full Text] [Related]
15. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
16. DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras.
Zhang X; Luukkonen LM; Eissler CL; Crowley VM; Yamashita Y; Schafroth MA; Kikuchi S; Weinstein DS; Symons KT; Nordin BE; Rodriguez JL; Wucherpfennig TG; Bauer LG; Dix MM; Stamos D; Kinsella TM; Simon GM; Baltgalvis KA; Cravatt BF
J Am Chem Soc; 2021 Apr; 143(13):5141-5149. PubMed ID: 33783207
[TBL] [Abstract][Full Text] [Related]
17. Reimagining Druggability Using Chemoproteomic Platforms.
Spradlin JN; Zhang E; Nomura DK
Acc Chem Res; 2021 Apr; 54(7):1801-1813. PubMed ID: 33733731
[TBL] [Abstract][Full Text] [Related]
18. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
Kiely-Collins H; Winter GE; Bernardes GJL
Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
[TBL] [Abstract][Full Text] [Related]
19. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
[TBL] [Abstract][Full Text] [Related]
20. Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery.
Pei J; Wang G; Feng L; Zhang J; Jiang T; Sun Q; Ouyang L
J Med Chem; 2021 Apr; 64(7):3493-3507. PubMed ID: 33764774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
